Patents by Inventor A. PRYNC

A. PRYNC has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process of Making Transgenic Mammals That Produce Exogenous Proteins in Milk and Transgenic Mammals Produced Thereby
    Publication number: 20090228999
    Abstract: The invention relates to a non-human transgenic mammal that is useful for the production of a protein of interest that may be toxic to the mammal. The mammal is characterized by the fact that it is transgenic for the production in its milk of an inactive form of the protein of interest, preferably recombinant human insulin. It is not possible to produce recombinant human insulin in transgenic mammals since this molecule has a certain degree of biological activity in the mammals and could be toxic to the mammal. Thus, the invention involves cloning a genetic construct comprising a sequence encoding a modified human insulin precursor under the control of a beta casein promoter in an expression vector. It also involves transfecting the expression plasmid into fetal bovine somatic cells, such as fibroblasts, and enucleating bovine oocytes by nuclear transfer to generate transgenic embryos.
    Type: Application
    Filed: June 13, 2008
    Publication date: September 10, 2009
    Applicant: Sterrenbeld Biotechnologie North America, Inc.
    Inventors: A. BERCOVICH, A. PRYNC, N. Fernandez, C. Melo, M. Criscuolo
  • Process for Producing Exogenous Protein in the Milk of Transgenic Mammals and a Process For Purifying Proteins Therefrom
    Publication number: 20090187999
    Abstract: The invention relates to a non-human transgenic mammal that is useful for the production of a protein of interest that may be toxic to the mammal. The mammal is characterized by the fact that it is transgenic for the production in its milk of an inactive form of the protein of interest, preferably recombinant human insulin. It is not possible to produce recombinant human insulin in transgenic mammals since this molecule has a certain degree of biological activity in the mammals and could be toxic to the mammal. Thus, the invention involves cloning a genetic construct comprising a sequence encoding a modified human insulin precursor under the control of a beta casein promoter in an expression vector. It also involves transfecting the expression plasmid into fetal bovine somatic cells, such as fibroblasts, and enucleating bovine oocytes by nuclear transfer to generate transgenic embryos.
    Type: Application
    Filed: June 13, 2008
    Publication date: July 23, 2009
    Applicant: Sterrenbeld Biotechnologie North America, Inc.
    Inventors: A. BERCOVICH, A. Prync, C. Melo, N. Fernandez, N. Judewicz, M. Criscuolo